The thylacine has long been an icon of human-caused extinction. In the 1800s and early 1900s, European colonizers in Tasmania wrongly blamed the dog-sized, tiger-striped, carnivorous marsupial for killing their sheep and chickens. The settlers slaughtered thylacines by the thousands, exchanging the animals skins for a government bounty. The last known thylacine spent its days pacing a zoo cage in Hobart, Tasmania, and died of neglect in 1936.
Now the wolflike creaturealso known as the Tasmanian tigeris poised to become an emblem of de-extinction, an initiative that seeks to create new versions of lost species. Colossal Biosciences, a Texas-based de-extinction company that made headlines last September when it revealed that it planned to bring back the woolly mammoth, announced today that its second project will be resurrecting the thylacine.
Australian scientists have been hoping since 1999 to use emerging genetic technologies to try to bring the thylacine back from the dead. When the species went extinct, Tasmania lost its top predator. In theory, reintroducing proxy thylacines could help restore balance to Tasmanias remaining forests by picking off sick or weak animals and controlling overabundant herbivores such as wallabies and kangaroos, some researchers say. But early attempts at cloning the animal from museum specimens DNA failed, and the effort has not attracted significant fundinguntil this year.
Colossal Biosciences, co-founded by Harvard University geneticist George Church and tech entrepreneur Ben Lamm, is working with the University of Melbournes Andrew Pask, who has already sequenced most of the thylacine genome. The thylacine is the perfect candidate for de-extinction, Pask says, because it died out relatively recently, good-quality DNA is available, and its prey and parts of its natural habitat still exist.
In March his team established the Thylacine Integrated Genetic Restoration Research Lab with a philanthropic gift of five million Australian dollars (about $3.6 million). Colossal is providing more than that sum, Pask sayshe wont divulge exactly how muchas well as access to equipment, another dedicated thylacine lab in Texas and a large team of researchers.
With this partnership established, Pask now says its reasonable to expect to have a de-extincted thylacine-ish thing in a decade. That first iteration might be 90 percent thylacine, he says, though the ultimate goal is more like 99.9 percent. Eventuallyafter many years of monitoring the engineered animals in a large enclosed areaColossals goal is to release a viable, genetically-diverse population of perhaps 100 proxy thylacines into the wild.
To resurrect the woolly mammoth, Colossals researchers plan to introduce mammoth genes into the genome of the Asian elephant, its closest living relative. They will then try to create an embryo carrying that modified DNA that could gestate in an African elephant surrogate or an artificial uterus. The resulting creature would not be a mammoth per se but rather a cold-adapted Artic elephant with small ears, shaggy hair, a domed forehead and curved tusks, Lamm says. Yet if he showed the creature to his grandmother, shed say thats a woolly mammoth, he adds.
Already, Lamm says, Colossal has fully sequenced the Asian and African elephant genomes, collected more than fifty mammoth genomes, and begun making edits to elephant cellsbut he thinks the thylacine could turn out to be easier to revive than the mammoth because of the gestation times involved. Both projects still face many hurdles, however.
For the thylacine, the first task is to complete the sequencing of the animals genome. Pasks lab has about 96 percent of it down, but the final 4 percent is the trickiest, he says. Its like doing one of those horrible puzzles thats all baked beans or all blue sky. Every bit looks the same, and were trying to figure out how it goes together.
Next the researchers will compare the genome of the thylacine to that of one of its closest living relatives: the fat-tailed dunnart, a mouse-sized marsupial that is relatively abundant and copes well in captivity. Using CRISPR gene-editing technology, the scientists will engineer the dunnarts genome to more closely resemble the thylacines.
The researchers have already figured out how to re-program dunnart skin cells into stem calls, and are currently testing them to see whether theyre capable of generating an entire embryosomething that hasnt yet been done in marsupials, which develop differently from placental mammals such as humans and mice. Once theyve fine-tuned the recipe, theyll be able to use the stem cells to create a gene-edited living embryo they can insert into either a dunnart mother or an artificial marsupial womb, which they would have to invent.
Thylacine pregnancies are estimated to last just a few weeks, compared with 22 months for mammoths. And like other newborn marsupials, the baby thylacines would be little larger than a grain of rice, so even a diminutive dunnart mother could nourish them in her pouch at first. But Lamm says Colossal will work on developing a synthetic pouch, as well as a marsupial milk formula appropriate for each stage of development.
Collectively, these new marsupial reproductive technologies could become crucial tools for the conservation of extant species such as koalas or numbats, Pask says. There is absolutely no way I would have the millions that I have now for marsupial conservation if I [wasnt] trying to bring the Tasmanian tiger back, he says.
Other scientists are considerably less optimistic about the project. Mammal expert Kris Helgen of the Australian Museum, who worked on sequencing the thylacines mitochondrial genome in 2009, thinks altering the dunnarts DNA to truly resemble a thylacines will be an impossible feat. The two species are separated by as much as 40 million years of evolution, he says. Thylacines are so unlike other animals that theyre in their own taxonomic family, just as dogs are in one family of mammals and catsfrom tigers to tabbiesare in another. Turning a dunnart into a thylacine, Helgen says, would be the equivalent of editing a dogs genome until the resulting animal looked like a cat. (Mammoths and elephants are far more closely related.)
Even if Colossal could overcome the technical challenges involved, the prospect of resurrecting the thylacine raises ethical concerns, according to Carol Freeman, an animal studies researcher at the University of Tasmania. The whole discourse is about bringing this animal back, but the welfare of the individual animals isnt really talked about, she says. Both dunnarts and almost-thylacines would inevitably suffer in the course of these experiments, which cannot be justified for such an uncertain result. It would be many years, if ever, that cloned thylacines could have anything like the life they may have hadand deservein the wild.
If the scientists do get to the point where they have actual living thylacines in hand, Pask says they would consult the public, including Indigenous communities, about any release. But Bradley Moggridge, a Kamilaroi environmental scientist at the University of Canberra in Australia, says Indigenous Australians should be involved nowespecially Tasmanian Aboriginal peoples, who were themselves hunted by white settlers in the 19th century. They may have ideas; they might need to get [their traditional lands] ready for this species. That could take a long time, he says. Discussions between the Colossal team and Indigenous Australians could be beneficial for everyone, Moggridge says. Aboriginal ecological knowledge about the thylacine would have been encoded in stories and songs, and de-extinction could reignite some of them, but the researchers need to start those conversations now.
Other critics worry the glamour of de-extinction will rob attention and funding from conservation projects. One study in 2017 found that allocating sums to existing endangered species programs rather than giving the same amount of money to de-extinction efforts would see about two to eight times as many species saved. Its better to spend the money on the living than the dead, lead author Joseph Bennett of Carleton University in Ontario told Science.
The idea that science could restore the thylacine is just so lovely; it captures the imagination, says Helgen, who once made a pilgrimage to visit every museum specimen of the animal in existence. But the thylacine is extinct in Australia and in Tasmania, and theres no way to bring it back. Some species are simply gone forever because of how unique they were, and the thylacine is one of them, he says. A few million dollars [are] not going to give us an escape hatch from extinction.
See the original post:
De-extinction Company Aims to Resurrect the Tasmanian Tiger - Scientific American
- Cardiovascular Glossary A-Z (All) | Texas Heart Institute - January 4th, 2023
- ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) - Business Wire - September 25th, 2022
- GVHD in the Context of Stem Cell or Allogeneic Transplant - Cancer Network - August 22nd, 2022
- Dean Kamen on the power of celebrating your own obsoletion - TechCrunch - July 27th, 2022
- Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL - OncLive - July 27th, 2022
- Unanticipated findings cast new light on the genetic regulation of different brain tumors - Baylor College of Medicine - July 27th, 2022
- Chaotic response in Uvalde, Parkland shooter faces death penalty, mall shooting leaves 3 dead and jury selection begins in Bannon trial | Hot off the... - July 19th, 2022
- Stem Cells, Abortion, Baby Parts, & the Ukraine - Physicians for Life - June 22nd, 2022
- INVECTYS, MD ANDERSON AND CTMC ANNOUNCE STRATEGIC COLLABORATION FOR CAR T CELL THERAPY DEVELOPMENT - BioSpace - June 22nd, 2022
- Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive... - June 13th, 2022
- Texas Family Fights to Access $2.1 Million Treatment for Baby - NBC 5 Dallas-Fort Worth - May 15th, 2022
- La Conner native raising funds to cure blood cancer - La Conner Weekly News - May 2nd, 2022
- CORRECTING and REPLACING -- Affimed NV - GlobeNewswire - May 2nd, 2022
- StudyFinds Blotter: Other Notable Health Research From April 28, 2022 - Study Finds - May 2nd, 2022
- Sung to lead cancer institute; Bankston wins fellowship - ASBMB Today - April 19th, 2022
- Houston teen first in Texas to become own donor to reverse sickle cell anemia - FOX 26 Houston - March 25th, 2022
- Oleic Acid, a Key to Activating the Brains Fountain of Youth - Neuroscience News - March 25th, 2022
- Stem Cell Therapy Boosts Outcomes for Some Heart Failure Patients - HealthDay - November 22nd, 2021
- Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed... - November 22nd, 2021
- BioBridge Global continues history of innovation with umbilical cord collection and processing under cGMP standards for further manufacture - Yahoo... - November 22nd, 2021
- Immatics to Present Update on Lead ACTengine Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancers 36th Annual Meeting - Yahoo... - November 8th, 2021
- Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual ... - Tyler Morning Telegraph - November 8th, 2021
- ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting - StreetInsider.com - November 8th, 2021
- The Power of the Immune System: New Treatment for Painful Blood Cancer Side Effect - Curetoday.com - October 28th, 2021
- Durham firm offering up to $10,000 for researchers to use its intestinal technology - WRAL Tech Wire - October 16th, 2021
- Elevated cryptic transcription emerges as a common theme in aging mammalian cells - Baylor College of Medicine News - August 31st, 2021
- Insulin-producing implants are being developed to control Type 1 diabetes - Health Europa - August 5th, 2021
- Cryptic Transcription in Mammalian Stem Cells Linked to Aging - Technology Networks - August 5th, 2021
- Overview of DLBCL - Targeted Oncology - August 5th, 2021
- The True Crime Junkies and the Curious Case of a Missing Husband - VICE - August 5th, 2021
- FROM THE LABS: Hispanic Heritage Spotlight: Interview with Dr. Nino Rainusso - Baylor College of Medicine News - November 13th, 2020
- UPMC nurse practitioner hailed 'healthcare hero' on live TV - Altoona Mirror - October 31st, 2020
- BrainStrom Cell Therapeutics (NASDAQ:BCLI) Enters Agreement With Catalent (NYSE:CTLT) For Manufacture Of Its NurOwn Cell Therapy - BP Journal - October 31st, 2020
- Dr. Daisy Ayim, Cosmetic Surgeon, ObGyn, Business Owner and Entrepreneur, Is Revolutionizing The Integration Of Women's Health And Cosmetic Care -... - October 31st, 2020
- Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West - October 21st, 2020
- Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma - Science... - October 21st, 2020
- Biotechnology could change the cattle industry. Will it succeed? - Salon - September 8th, 2020
- STEM CELLS | VitaDrip IV Therapy | Texas - June 26th, 2020
- New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring's Plinabulin - BioSpace - June 23rd, 2020
- Tau: Why Alzheimer's Worsens Fast in Some, Slowly in Others - Alzforum - June 23rd, 2020
- Scholarly Perspectives on COVID-19, Part 1: This Was Only a Matter of Time - Southern Newsroom - June 23rd, 2020
- Texas Stem Cell Law Opens Door for Controversial Treatments - June 11th, 2020
- Who's to blame? These three scientists are at the heart of the Surgisphere COVID-19 scandal - Science Magazine - June 9th, 2020
- FTC ramps up enforcement with new wave of warning letters - NutraIngredients-usa.com - June 9th, 2020
- UT Student Awarded Prestigious Astronaut Scholarship - UT News | The University of Texas at Austin - June 9th, 2020
- South Sound Community Bands Together To Save Local Lives - southsoundtalk.com - May 7th, 2020
- Pfizer, NYU working on innovative coronavirus vaccine that could be ready by end of summer - NBC News - May 7th, 2020
- How industry hopes to take on COVID-19 - Bioprocess Insider - BioProcess Insider - March 8th, 2020
- Meng Hsieh, Andrew Shubin - The New York Times - March 8th, 2020
- Jimbo Fisher's Kidz1stFund, Aggie Corps of Cadets team up for Be the Match bone marrow donor registry drive - Bryan-College Station Eagle - March 2nd, 2020
- Texas A&M Researcher Named To National List Of Inspiring Black Scientists - Texas A&M University - March 2nd, 2020
- What to do in Madison: March 2-8, 2020 - The Bozho - March 2nd, 2020
- Cumberland County family turns to non-FDA approved stem cell treatment to help two-year-old son with cerebral palsy - FOX43.com - February 27th, 2020
- Recombinetics Announces Collaboration with University of Texas Southwestern to Advance Regenerative Medicine Through Therapeutic Cell, Tissue, and... - February 27th, 2020
- Stem Cell Therapy for Joints & Spine in Austin Texas - January 28th, 2020
- El Paso scientists to deliver 3D bioprinted miniature hearts to the ISS - 3D Printing Industry - January 28th, 2020
- El Paso scientists team up for heart research project at the International Space Station - KVIA El Paso - January 28th, 2020
- Drugs, Biologics, and Regenerative Medicine in 2019: A Successful Year Ends with Promise of a More Challenging 2020 - JD Supra - December 18th, 2019
- Incoming Faculty Bring New Areas of Research to Rensselaer - Rensselaer Polytechnic Institute - September 24th, 2019
- Nivolumab as an addition to frontline therapy of AML in younger patients - AML Global Portal - September 24th, 2019
- Interview: BIOLIFE4D is The First US Company to Bioprint a Mini-Heart (for Cardiotoxicity Testing) - 3DPrint.com - September 24th, 2019
- Stem cells regrow leg's long bones - WNDU-TV - September 22nd, 2019
- A breakthrough in the battle against citrus greening - Gainesville Sun - September 22nd, 2019
- Comparing Mymetics (OTCMKTS:MYMX) & Crispr Therapeutics (OTCMKTS:CRSP) - TechNewsObserver - September 22nd, 2019
- STEM CELL THERAPY & TREATMENTS Texas Regional Health - September 10th, 2019
- Fast Facts: Stem Cells 101 Vital Record - September 10th, 2019
- Keller, TX Stem Cells | Neuropathy & Pain Centers of Texas - May 31st, 2019
- Arlington Stem Cells | Neuropathy & Pain Centers of Texas - May 1st, 2019
- Houston, Texas Stem Cell Transplants, Richmond, Sugar Land ... - April 21st, 2019
- Fort Worth Stem Cells | Neuropathy and Pain Centers of Texas - April 15th, 2019
- Stem Cell Rejuvenation Therapy | Totalhormonegenetherapy.com - April 15th, 2019
- Our Doctors - Knee Stem Cells - March 17th, 2019
- Stem Cell Treatment Center in Dallas, Texas | Stem Cell ... - March 17th, 2019
- Neuropathy & Pain Centers of Texas - Stem Cells & Neuropathy - February 6th, 2019
- Stem Cell Doctor Dallas Dr. Darcy Brunk | Dallas, Plano ... - January 25th, 2019
- Four Types of Stem Cells - Texas Right to Life - December 15th, 2018
- Texas | The Stem Cellar - December 5th, 2018
- Dallas, Texas, Stem Cells Treatment, Legal, Ft. Worth ... - November 16th, 2018
- HB810 | Right to Try Law | Texas Stem Cell Law | StemGenex - October 13th, 2018
- Shooting Up Stem Cells With Ben Greenfield The Down The ... - September 16th, 2018